Psychosomatic Misdiagnosis Can Have Lasting Negative Impact on Patients
By Lori Solomon and Farrokh Sohrabi, M.D. HealthDay Reporters
MONDAY, March. 3, 2025 -- Chronic diseases misdiagnosed as psychosomatic can lead to long-term damage to patients' physical and mental well-being, according to a study published online March 3 in Rheumatology.
Melanie Sloan, Dr.P.H., from the University of Cambridge in the United Kingdom, and colleagues examined the impacts of psychosomatic and psychiatric misdiagnoses on patients with systemic autoimmune rheumatic diseases (SARDs). The analysis included 3,396 participants in two SARDs cohorts.
The researchers found that >80 percent of patients reported that perceived psychosomatic and psychiatric misdiagnoses damaged their self-worth, and 72 percent reported that it still upset them. Compared with patients reporting no psychosomatic or psychiatric misdiagnoses, lower mental well-being and higher depression and anxiety levels were seen among patients reporting psychosomatic and/or psychiatric misdiagnoses, along with lower levels of satisfaction with every aspect of medical care. Misdiagnoses were associated with a significantly higher likelihood of underreporting symptoms and health care avoidance, but they were not associated with medication adherence.
"Although many doctors were intending to be reassuring in suggesting a psychosomatic or psychiatric cause for initially unexplainable symptoms, these types of misdiagnoses can create a multitude of negative feelings and impacts on lives, self-worth, and care," Sloan said in a statement. "These appear to rarely be resolved even after the correct diagnoses. We must do better at helping these patients heal, and in educating clinicians to consider autoimmunity at an earlier stage."
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-04 06:00
Read more
- Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
- Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
- FDA Approves Filkri (filgrastim-laha), a Biosimilar to Neupogen
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- FDA Approves Label Update for Kite’s Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions